This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Management of diabetes insipidus

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Seek expert help.

Identify cause.

Mild cases of cranial diabetes insipidus i.e. urine output less than 3-4 litres per 24 hr may be treated adequately by sufficient fluid intake.

Moderate / severe cases are treated with desmopressin 5-40 mcg intranasally. The lowest treatment dose that controls polyuria is used - the risk of hyponatraemia is increased with increasing dose of desmopressin.

  • Symptoms of under-replacement with desmopressin are thirst and polyuria, while symptoms of over-replacement are headache and mild confusion (due to hyponatremia) and reduced urine output (1)

Other treatment options include:

Chlorpropamide 250-500 mg/day or carbamazepine 400-800 mg/day may be used to reduce urine volume by up to 50%

  • chlorpropamide enhances the effects of ADH on the renal collecting tubule
  • carbamazepine exerts its effects centrally

Familial cases of nephrogenic diabetes insipidus benefit from thiazide diuretics, indomethacin and high dose desmopressin, singly or in combination. Acquired cases require correction of the underlying abnormality.

References:

  1. Levy M, Prentice M, Wass J. Diabetes insipidus. BMJ. 2019 Feb 28;364:l321. doi: 10.1136/bmj.l321.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.